Cartesian Therapeutics Inc (NAS:RNAC)

$ 18.19 0.28 (1.56%) Market Cap: 462.30 Mil Enterprise Value: 257.75 Mil PE Ratio: 0 PB Ratio: 606.33 GF Score: 56/100

Selecta Biosciences Inc and Cartesian Therapeutics Inc Merger Conference Call Transcript
Nov 13, 2023
Q2 2023 Selecta Biosciences Inc Earnings Call Transcript
Aug 17, 2023

$33.6 (+2.75%)

Earnings
Q1 2023 Selecta Biosciences Inc Earnings Call Transcript
May 04, 2023

$32.1 (-6.96%)

Earnings
Selecta Biosciences Inc Reports DISSOLVE Phase 3 Clinical Trials in Chronic Refractory Gout Transcript
Mar 21, 2023
Q4 2022 Selecta Biosciences Inc Earnings Call Transcript
Mar 02, 2023

$47.4 (-1.25%)

Earnings
Q3 2022 Selecta Biosciences Inc Earnings Call Transcript
Nov 03, 2022

$50.7 (+3.68%)

Earnings
Q2 2022 Selecta Biosciences Inc Earnings Call Transcript
Aug 04, 2022

$56.4 (+13.94%)

Earnings
Q1 2022 Selecta Biosciences Inc Earnings Call Transcript
May 05, 2022

$24.3 (+1.12%)

Earnings
Q4 2021 Selecta Biosciences Inc Earnings Call Transcript
Mar 10, 2022

$52.5

Earnings
Q3 2021 Selecta Biosciences Inc Earnings Call Transcript
Nov 09, 2021

$115.5 (-2.78%)

Earnings
Selecta Biosciences Inc Phase I SEL-399 AAV Data Results Call Transcript
Nov 08, 2021
Selecta Biosciences Inc at Jefferies Gene Therapy/Editing Summit (Virtual) Transcript
Oct 27, 2021
Q2 2021 Selecta Biosciences Inc Earnings Call Transcript
Aug 12, 2021

$131.1 (+14.40%)

Earnings
Selecta Biosciences Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 23, 2021
Q1 2021 Selecta Biosciences Inc Earnings Call Transcript
May 13, 2021

$87.9 (-2.33%)

Earnings
Q4 2020 Selecta Biosciences Inc Earnings Call Transcript
Mar 11, 2021

$117

Earnings
Q3 2020 Selecta Biosciences Inc Earnings Call Transcript
Nov 05, 2020

$97.2 (-1.82%)

Earnings
Selecta Biosciences, Inc. - Special Call Transcript
Sep 30, 2020
Q2 2020 Selecta Biosciences Inc Earnings Call Transcript
Aug 06, 2020

$75.6 (-9.35%)

Earnings
Selecta Biosciences Inc Annual Shareholders Meeting Transcript
Jun 19, 2020
Selecta Biosciences Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 12, 2020
Q1 2020 Selecta Biosciences Inc Earnings Call Transcript
May 07, 2020

$90 (-2.91%)

Earnings
Q4 2019 Selecta Biosciences Inc Earnings Call Transcript
Mar 12, 2020

$62.4 (-32.69%)

Earnings
Q3 2019 Selecta Biosciences Inc Earnings Call Transcript
Nov 08, 2019

$41.7 (-9.74%)

Earnings
Q2 2019 Selecta Biosciences Inc Earnings Call Transcript
Aug 08, 2019

$53.4 (-7.29%)

Earnings
Selecta Biosciences Inc Annual Shareholders Meeting Transcript
Jun 14, 2019
Q1 2019 Selecta Biosciences Inc Earnings Call Transcript
May 09, 2019

$72 (-3.61%)

Earnings
Q4 2018 Selecta Biosciences Inc Earnings Call Transcript
Mar 15, 2019

$65.1 (-2.25%)

Earnings

Selecta Biosciences, Inc. - Special Call Transcript

Sep 30, 2020 / 09:30PM GMT

Release Date Price: $74.4 (-3.12%)

Transcript 8-K

Operator

Good afternoon, and welcome to the Selecta Biosciences Phase II COMPARE Conference Call. (Operator Instructions) For opening remarks, I would like to introduce Brad Dahms, Chief Financial Officer of Selecta. Please go ahead, sir.

Bradford D. Dahms

Selecta Biosciences, Inc. - CFO, Principal Financial Officer & Principal Accounting Officer

Thank you, and good afternoon. During this call, we will discuss top line results from the Phase II COMPARE study of SEL-212, a novel treatment for chronic refractory gout versus pegloticase. The press release reporting the results and the presentation that Carsten and Peter will walk through are available in the Investors & Media section of our website, www.selectabio.com.

Joining me today are Carsten Brunn, our President and Chief Executive Officer; and Dr. Peter G. Traber, our Chief Medical Officer. During today's call, we will be making certain forward-looking statements, including, without limitation, statements about the potential safety,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.